Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Tarsus Pharmaceuticals, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | | 100.0% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | 0.0% | | 3.4% | 6.1% | 0.0% | 5.2% | 0.0% |
| Gross profit | | 100.0% | | 96.6% | 93.9% | 100.0% | 94.8% | 100.0% |
| Research and development | | 494.2% | | 62.9% | 2241.4% | 2378.1% | 823.3% | 32.7% |
| General and administrative | | 603.8% | | 67.9% | 1474.2% | 2003.6% | 538.0% | 30.9% |
| EBITDA | | -993.9% | | -33.6% | -3614.1% | -4262.7% | -1259.8% | 33.6% |
| Depreciation | | 4.2% | | 0.6% | 7.6% | 11.8% | 6.7% | 0.6% |
| EBIT | | -998.1% | | -34.2% | -3621.7% | -4274.6% | -1266.5% | 33.1% |
| Pre-tax income | | -936.8% | | -37.6% | -3754.9% | -4377.2% | -1238.4% | 28.7% |
| Income taxes | | 0.0% | | 0.0% | -0.2% | 16.6% | 27.5% | -0.1% |
| Net income | | -936.8% | | -37.6% | -3754.7% | -4393.8% | -1265.9% | 28.8% |
|